Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Nutex Health (NUTX) over the last 7 years, with Q2 2020 value amounting to $7.2 million.

  • Nutex Health's Cash & Equivalents rose 25397.69% to $166.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.0 million, marking a year-over-year increase of 25397.69%. This contributed to the annual value of $40.6 million for FY2024, which is 8471.0% up from last year.
  • Per Nutex Health's latest filing, its Cash & Equivalents stood at $166.0 million for Q3 2025, which was up 25397.69% from $96.7 million recorded in Q2 2025.
  • Over the past 5 years, Nutex Health's Cash & Equivalents peaked at $166.0 million during Q3 2025, and registered a low of $3.7 million during Q1 2021.
  • Moreover, its 5-year median value for Cash & Equivalents was $34.3 million (2022), whereas its average is $42.2 million.
  • Its Revenue - Interest and Investment Income has fluctuated over the past 5 years, first tumbled by 4795.14% in 2018, then surged by 60783.83% in 2020.
  • Quarter analysis of 4 years shows Nutex Health's Revenue - Interest and Investment Income stood at $2.4 million in 2017, then plummeted by 47.95% to $1.2 million in 2018, then skyrocketed by 442.77% to $6.7 million in 2019, then rose by 7.21% to $7.2 million in 2020.
  • Its Cash & Equivalents was $166.0 million in Q3 2025, compared to $96.7 million in Q2 2025 and $84.7 million in Q1 2025.